Getting Access

04/27/22 • 21 min

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse.

And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the path to reimbursement and, ultimately, access for innovative therapies when they hit the market.

Jon Haas, Senior Director, Market Access at Syneos Health, discusses the complex process, how companies can best position their product for access and what really matters to payers in the long run.

For more on value and access in biopharma, check out:

How Competition Affects Market Access for Rare Disease Therapeutics, Part 1

How Competition Affects Market Access for Rare Disease Therapeutics, Part 2

Future-Forward Planning: What Drug and Device Manufacturers Need to Know About Preventive Drug Lists

2021 Update: Non-Personal Promotion: What Do Payers Want?

The Other Path to Access: Strategies for Direct Employer Engagement

The Syneos Health Podcast: Trade and Distribution in Pharma: It's Complicated

What to Expect on Drug Pricing in the Democratic Trifecta

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse.

Jon Haas, Senior Director, Market Access at Syneos Health, discusses the complex process, how companies can best position their product for access and what really matters to payers in the long run.

For more on value and access in biopharma, check out:

How Competition Affects Market Access for Rare Disease Therapeutics, Part 1

How Competition Affects Market Access for Rare Disease Therapeutics, Part 2

Future-Forward Planning: What Drug and Device Manufacturers Need to Know About Preventive Drug Lists

2021 Update: Non-Personal Promotion: What Do Payers Want?

The Other Path to Access: Strategies for Direct Employer Engagement

The Syneos Health Podcast: Trade and Distribution in Pharma: It's Complicated

What to Expect on Drug Pricing in the Democratic Trifecta

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].

Previous Episode

Epilepsy, the Central Nervous System and Rare Disease

Nobody thinks about epilepsy as a rare disease. But epilepsy syndromes actually make up a large portion of CNS rare diseases. And while progress has been made in developing therapies that treat the symptoms of epilepsy, the true underlying causes can be difficult to pinpoint and treat.

But progress is being made, and Nermina Nakas, MD, MPH and Jane Williams, MD, MPH, Executive Medical Directors in CNS at Syneos Health – and contributors to the book Rare Disease Drug Development: Clinical, Scientific, Patient and Caregiver Perspectives – join Jeff Stewart to discuss recent developments in rare disease epilepsy clinical trials, what they have learned and what drug developers need to know about treating young patients with neurological rare diseases.

For more on the topics covered in this episode, be sure to check out:

Innovation Perspectives in Rare Disease Drug Development

The Syneos Health Podcast: Navigating the Rare Disease Landscape

The Syneos Health Podcast: Mental Health in Rare Disease

Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].

Next Episode

Training the Next Generation of Pharma

The clinical research enterprise faces a clear and present personnel shortage, creating inefficiencies for clinical trial sponsors and contract research organizations, many of whom find themselves in a constant recruitment cycle for qualified clinical research associates (CRAs) in a hyper-competitive job market.

While industry has traditionally recruited for these roles from healthcare and scientific programs or settings, we are now seeing a shift from requiring that specific, role-based experience to a more foundational competency-based model. This means potentially looking outside of those traditional sources. But how to we find, recruit and train this next generation?

Jennifer Sozio, Senior Vice President, Clinical Operations and Audra Holleman, Vice President, Clinical Development at Syneos Health discuss the new profile of CRA candidates, challenges and opportunities for recruitment in the current market, and how to train and prepare a growing pool of new CRA resources focused on quality, project delivery and commitment to advancement.

Learn more about the Syneos Health Clinical Training Institute here.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].